Free Trial

Axsome Therapeutics (NASDAQ:AXSM) Receives "Buy" Rating from Needham & Company LLC

Axsome Therapeutics logo with Medical background
Remove Ads

Needham & Company LLC reaffirmed their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM - Free Report) in a research report sent to investors on Monday morning,Benzinga reports. The brokerage currently has a $153.00 target price on the stock.

AXSM has been the subject of a number of other reports. HC Wainwright increased their price target on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the company a "buy" rating in a report on Thursday, February 20th. Robert W. Baird increased their target price on shares of Axsome Therapeutics from $132.00 to $160.00 and gave the company an "outperform" rating in a research note on Monday. Cantor Fitzgerald restated an "overweight" rating and set a $153.00 price target on shares of Axsome Therapeutics in a research note on Wednesday, February 19th. Bank of America upped their price target on Axsome Therapeutics from $143.00 to $167.00 and gave the company a "buy" rating in a report on Tuesday, February 11th. Finally, William Blair reaffirmed an "outperform" rating on shares of Axsome Therapeutics in a research report on Tuesday, February 18th. One equities research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat.com, Axsome Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $167.36.

Check Out Our Latest Stock Report on Axsome Therapeutics

Remove Ads

Axsome Therapeutics Stock Down 0.6 %

Shares of NASDAQ AXSM traded down $0.69 during mid-day trading on Monday, reaching $124.41. 554,174 shares of the company traded hands, compared to its average volume of 1,040,204. The company's fifty day moving average is $107.34 and its two-hundred day moving average is $97.28. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. Axsome Therapeutics has a fifty-two week low of $64.11 and a fifty-two week high of $139.13. The stock has a market cap of $6.07 billion, a PE ratio of -20.77 and a beta of 0.99.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The company had revenue of $118.77 million during the quarter, compared to analysts' expectations of $117.83 million. On average, analysts expect that Axsome Therapeutics will post -2.79 earnings per share for the current year.

Insider Buying and Selling at Axsome Therapeutics

In other news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now owns 42,187 shares in the company, valued at approximately $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 22.40% of the company's stock.

Institutional Investors Weigh In On Axsome Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Pitcairn Co. grew its holdings in shares of Axsome Therapeutics by 3.4% during the fourth quarter. Pitcairn Co. now owns 4,562 shares of the company's stock worth $386,000 after purchasing an additional 148 shares during the last quarter. Meridian Wealth Management LLC lifted its position in Axsome Therapeutics by 0.7% during the 4th quarter. Meridian Wealth Management LLC now owns 21,171 shares of the company's stock worth $1,791,000 after buying an additional 150 shares in the last quarter. Summit Investment Advisors Inc. grew its holdings in Axsome Therapeutics by 4.4% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,852 shares of the company's stock worth $326,000 after acquiring an additional 162 shares during the last quarter. Arizona State Retirement System increased its position in Axsome Therapeutics by 1.8% in the 4th quarter. Arizona State Retirement System now owns 9,054 shares of the company's stock valued at $766,000 after acquiring an additional 164 shares in the last quarter. Finally, Intrust Bank NA raised its stake in shares of Axsome Therapeutics by 6.9% in the fourth quarter. Intrust Bank NA now owns 2,823 shares of the company's stock worth $239,000 after acquiring an additional 183 shares during the last quarter. 81.49% of the stock is owned by institutional investors and hedge funds.

About Axsome Therapeutics

(Get Free Report)

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

See Also

Analyst Recommendations for Axsome Therapeutics (NASDAQ:AXSM)

Should You Invest $1,000 in Axsome Therapeutics Right Now?

Before you consider Axsome Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.

While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads